Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial - Concepedia

Concepedia

Publication | Open Access

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial

DOI Full Paper Access

35

Citations

17

References

2024

Year

Tanja Fehm, Francesco Cottone, Kyle Dunton, Fabrice André, Ian E. Krop, Yeon Hee Park, Michelino De Laurentiis, Yasuo Miyoshi, Anne Armstrong, Manuel Ruíz Borrego,

The Lancet Oncology

References

	Year	Citations

Page 1